In yesterday’s Wall Street session, Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) shares traded at $1.34, up 3.88% from the previous session.
As of this writing, 2 analysts cover Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $22.00 and a low of $6.70, we find $14.35. Given the previous closing price of $1.29, this indicates a potential upside of 1012.4 percent. SONN stock price is now 10.56% away from the 50-day moving average and -54.26% away from the 200-day moving average. The market capitalization of the company currently stands at $11.52M.
There are 0 analysts who have given it a hold rating, whereas 2 have given it a buy rating. Brokers who have rated the stock have averaged $14.35 as their price target over the next twelve months.
Insiders disposed of 4,507 shares of company stock worth roughly $6039.38 over the past 1 year. A total of 2.13% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SONN stock. A new stake in Sonnet BioTherapeutics Holdings Inc. shares was purchased by VIRTU FINANCIAL LLC during the first quarter worth $36,000. MARINER, LLC invested $18,000 in shares of SONN during the first quarter. In total, there are 20 active investors with 3.50% ownership of the company’s stock.
Monday morning saw Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN) opened at $1.6800. During the past 12 months, Sonnet BioTherapeutics Holdings Inc. has had a low of $0.91 and a high of $9.37. The fifty day moving average price for SONN is $1.2158 and a two-hundred day moving average price translates $2.9088 for the stock.
The latest earnings results from Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$1.82, beating analysts’ expectations of -$1.96 by 0.14. This compares to -$1.15 EPS in the same period last year. For the current quarter, analysts expect SONN to generate $100k in revenue.
Sonnet BioTherapeutics Holdings Inc.(SONN) Company Profile
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.